載入...
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective...
Na minha lista:
| 發表在: | Genes (Basel) |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8228461/ https://ncbi.nlm.nih.gov/pubmed/34200676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/genes12060899 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|